Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma

Mei, Peng-jin; Bai, Jing; Miao, Faan; Li, Zhong-Lin; Chen, Chen; Zheng, Jian; Fan, Yi‐Ming

doi:10.1007/s10637-018-0667-9

Cited by 20 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we observed that XRCC1 expression was up-regulated in GBC compared with non-tumor tissues, which was consistent with previous studies where XRCC1 was overexpression in ovarian cancer and head and neck squamous cell cancer (Ang et al, 2011;Abdel-Fatah et al, 2013). On the contrary, several reports showed that XRCC1 was down-regulated in glioma, bladder cancer, pancreatic cancer, and gastric cancer (Crnogorac-Jurcevic et al, 2002;Sak et al, 2005;Wang et al, 2012;Mei et al, 2019). This contradiction may be owed to the organ specificity.…”

Section: Discussionsupporting

confidence: 91%

“…Herein, we firstly studied the biological role of XRCC1 in CD133 + GBC-SD cells. Unexpectedly, the functional experiments revealed that knockdown of XRCC1 had no significant effect on the ability of proliferation, migration, invasion, and apoptosis in CD133 + GBC-SD cells, which was inconsistent with previous researches (Li et al, 2018;Mei et al, 2019). This inconsistency may be caused by cell specificity.…”

Section: Discussioncontrasting

confidence: 61%

“…Previous studies have demonstrated that XRCC1 plays a role in regulating cell biological features such as proliferation, migration, invasion, and drug resistance in several human cancer cell lines (Xu et al, 2014;Meng et al, 2017;Li et al, 2018;Mei et al, 2019). However, there is no study reporting the function of XRCC1 in gallbladder cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…As a BER protein, x-ray repair cross-complementing group 1 (XRCC1), a 70-kDa protein, is encoded by the gene located on chromosome 19q13.2-13.3 (Thompson and West, 2000). XRCC1 functions as a scaffold protein in the BER and its aberrant expression is associated with carcinogenesis of multiply human malignant tumors (Hanssen-Bauer et al, 2012;Meng et al, 2017;Mei et al, 2019). Currently, researches on XRCC1 mainly concentrate on the relationship between gene polymorphism and cancer susceptibility.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer

Miao

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Gallbladder cancer is a relatively uncommon human malignant tumor with an extremely poor prognosis. Currently, no biomarkers can accurately diagnose gallbladder cancer and predict patients' prognosis. XRCC1 is involved in tumorigenesis, progression, and chemo-resistance of several human cancers, but the role of XRCC1 in gallbladder cancer is never reported. In this study, we investigated the expression of XRCC1 and its clinicopathological and prognostic significance in gallbladder cancer, and explored the biological role of XRCC1 in gallbladder cancer cells. We found that XRCC1 was significantly up-regulated in gallbladder cancer in protein and mRNA levels. Positive XRCC1 expression was correlated with aggressive clinicopathological features and was an independent poor prognostic factor in gallbladder cancer. The ROC curves suggested that XRCC1 expression had potential clinicopathological diagnostic value in gallbladder cancer. In vitro, XRCC1 was overexpression in CD133 + GBC-SD cells compared to GBC-SD cells. In functional experiment, XRCC1 knockdown had a non-significant impact on proliferation, migration, invasion, and apoptosis of CD133 + GBC-SD cells. But, XRCC1 knockdown could significantly improve the sensitivity of CD133 + GBC-SD cells to 5-Fluorouracil via promoting cell necrosis and apoptosis. Thus, this study indicates that XRCC1 may be a promising predictive biomarker of gallbladder cancer and a potential therapeutic target for gallbladder cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer

Miao

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Cell viability was examined using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) as previously described [27]. U87 or C6 cells were seeded in triplicate on 96-well plates (3000 cells per well).…”

Section: Cck-8 Assaymentioning

confidence: 99%

RETRACTED ARTICLE: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway

Liu

Wang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Activation of nuclear factor-kappa B (NF-κΒ) through DNA damage is one of the causes of tumor cell resistance to radiotherapy. Chromosome region 1 (CRM1) regulates tumor cell proliferation, drug resistance, and radiation resistance by regulating the nuclear-cytoplasmic translocation of important tumor suppressor proteins or protooncoproteins. A large number of studies have reported that inhibition of CRM1 suppresses the activation of NF-κΒ. Thus, we hypothesize that the reversible CRM1 inhibitor S109 may induce radiosensitivity in glioblastoma (GBM) by regulating the NF-κΒ signaling pathway. Methods: This study utilized the cell counting kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU), and colony formation assay to evaluate the effect of S109 combined with radiotherapy on the proliferation and survival of GBM cells. The therapeutic efficacy of S109 combined with radiotherapy was evaluated in vivo to explore the therapeutic mechanism of S109-induced GBM radiosensitization. Results: We found that S109 combined with radiotherapy significantly inhibited GBM cell proliferation and colony formation. By regulating the levels of multiple cell cycle-and apoptosis-related proteins, the combination therapy induced G1 cell cycle arrest in GBM cells. In vivo studies showed that S109 combined with radiotherapy significantly inhibited the growth of intracranial GBM and prolonged survival. Importantly, we found that S109 combined with radiotherapy promoted the nuclear accumulation of IκΒα, and inhibited phosphorylation of p65 and the transcriptional activation of NF-κΒ. Conclusion: Our findings provide a new therapeutic regimen for improving GBM radiosensitivity as well as a scientific basis for further clinical trials to evaluate this combination therapy.

show abstract

Hsa_circ_0012563 promotes migration and invasion of esophageal squamous cell carcinoma by regulating XRCC1/EMT pathway

Zhang

Xiong

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Recent reports have indicated that circular RNA (circRNA) may regulate tumorigenesis development. However, the function of circRNAs in esophageal squamous cell carcinoma (ESCC) is unclear. Material and method The RT‐qPCR assay was performed to detect hsa_circ_0012563 expression in ESCC tissues and cell lines. Then, the MTT assay, colony formation assay, flow cytometric assay, and cell migration and invasion assay were performed to examine the function of hsa_circ_0012563. In addition, the RT‐PCR and Western blot were used to detect XRCC1 and epithelial‐to‐mesenchymal transition (EMT) related gene expression. Results The RT‐qPCR revealed that the hsa_circ_0012563 expression was remarkably upregulated in ESCC tissue and ESCC cell lines. Functionally, downregulation of hsa_circ_0012563 suppressed cell proliferation, migration, and invasion and promoted cell apoptosis. Mechanically, the knockdown of hsa_circ_0012563 inhibited XRCC1‐mediated EMT pathway to suppress cell migration and invasion. Conclusions Therefore, these results reveal hsa_circ_0012563 is a critical oncogene and may be a novel biomarker in ESCC.

show abstract

Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma

Cited by 20 publications

References 43 publications

XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer

XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer

RETRACTED ARTICLE: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway

Hsa_circ_0012563 promotes migration and invasion of esophageal squamous cell carcinoma by regulating XRCC1/EMT pathway

Contact Info

Product

Resources

About